This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sparreboom, A. Articles by Beijnen, J. H. Search for Related Content PubMed PubMed Citation Articles by Sparreboom, A. Articles by Beijnen, J. H.

Nonlinear Pharmacokinetics of Paclitaxel in Mice Results from the Pharmaceutical Vehicle Cremophor EL

Department of Clinical Chemistry, Antoni van Leeuwenhoek Huis, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam [A. S., O. v. T., W. J. N.], Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam [J. H. B.] and Department of Analysis and Toxicology, Faculty of Pharmacy, Utrecht University, P.O. Box 80082, 3508 TB Utrecht [J. H. B.], the Netherlands

Studies in humans and mice have demonstrated a nonlinear pharmacokinetic behavior of paclitaxel. Because of its poor water solubility, the drug is formulated in a mixture of Cremophor EL and ethanol (1:1, v/v; Taxol). We hypothesized that the substantial amounts of concurrently administered Cremophor EL could have a major influence on the pharmacokinetic behavior of paclitaxel. To determine the effect of the pharmaceutical vehicel Cremophor EL on the disposition of paclitaxel, female FVB mice received paclitaxel by i.v. injection at dose levels of 2, 10, and 20 mg/kg by appropriate (standard) dilution of the commercially available formulation of paclitaxel (Taxol) with saline. The drug was also given at 2 mg/kg with supplemented Cremophor EL-ethanol to achieve the same amount of vehicle as by standard administration of 10 mg/kg. Furthermore, paclitaxel formulations in Tween 80-ethanol (1:1, v/v) and dimethylacetamide were tested. Plasma samples were collected between 5 min and 48 h, and tissue specimens were sampled at 1, 4, and 8 h after drug administration. Paclitaxel and metabolites were quantified by high-performance liquid chromatography. Cremophor EL levels were determined by a novel high-performance liquid chromatography procedure. For comparative reasons, Cremophor EL was also assayed in plasma samples from three patients receiving a 3-h i.v. infusion of 175 mg/m² of paclitaxel. A marked nonlinear pharmacokinetic behavior of paclitaxel was observed when the drug was formulated in Cremophor EL-ethanol. The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively. When 2 mg/kg were given with an amount of Cremophor EL-ethanol matching that of the 10-mg/kg dose level, the clearance was 0.56 L/h/kg. If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively. Despite the fact that much higher plasma levels of paclitaxel are reached when given in the Cremophor EL-ethanol formulation, the tissue levels were essentially similar with all tested drug preparations. The Cremophor EL levels in patients were in the same order of magnitude as those observed in mice after administration of 2 and 10 mg/kg. These data demonstrate that Cremophor EL has a profound effect on the pharmacokinetics of paclitaxel in mice. Because Cremophor EL levels in mice and humans are within the same range, it is very likely that Cremophor EL also contributes substantially to the nonlinear pharmacokinetic behavior of paclitaxel observed in humans.

¹ To whom requests for reprints should be addressed. Phone: 31-20-5122792; Fax: 31-20-6172625.

Received 11/20/95. Accepted 3/ 1/96.

This article has been cited by other articles:

				Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, and H. Dai Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment Cancer Res., August 15, 2008; 68(16): 6652 - 6660. [Abstract] [Full Text] [PDF]

				D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]

				L. E. Broker, S. A. Veltkamp, E. I. Heath, B. C. Kuenen, H. Gall, L. Astier, S. Parker, L. Kayitalire, P. M. Lorusso, J. H.M. Schellens, et al. A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 Clin. Cancer Res., July 1, 2007; 13(13): 3906 - 3912. [Abstract] [Full Text] [PDF]

				A. H. Kyle, L. A. Huxham, D. M. Yeoman, and A. I. Minchinton Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2804 - 2810. [Abstract] [Full Text] [PDF]

				Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice Clin. Cancer Res., August 1, 2006; 12(15): 4695 - 4701. [Abstract] [Full Text] [PDF]

				K. L. Hennenfent and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Onc., May 1, 2006; 17(5): 735 - 749. [Abstract] [Full Text] [PDF]

				M. Joerger, A. D.R. Huitema, D. H.J.G. van den Bongard, J. H.M. Schellens, and J. H. Beijnen Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2150 - 2157. [Abstract] [Full Text] [PDF]

				S. Mielke, A. Sparreboom, S. M. Steinberg, H. Gelderblom, C. Unger, D. Behringer, and K. Mross Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4843 - 4850. [Abstract] [Full Text] [PDF]

				Y. Zou, H. Fu, S. Ghosh, D. Farquhar, and J. Klostergaard Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7382 - 7391. [Abstract] [Full Text] [PDF]

				J. Gligorov and J. P. Lotz Preclinical Pharmacology of the Taxanes: Implications of the Differences Oncologist, June 2, 2004; 9(suppl_2): 3 - 8. [Abstract] [Full Text] [PDF]

				J. R. Rigas Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review Oncologist, June 2, 2004; 9(suppl_2): 16 - 23. [Abstract] [Full Text] [PDF]

				T.-Y. Kim, D.-W. Kim, J.-Y. Chung, S. G. Shin, S.-C. Kim, D. S. Heo, N. K. Kim, and Y.-J. Bang Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies Clin. Cancer Res., June 1, 2004; 10(11): 3708 - 3716. [Abstract] [Full Text] [PDF]

				M. E. de Jonge, H. J. G. D. van den Bongard, A. D. R. Huitema, R. A. A. Mathot, H. Rosing, P. Baas, N. van Zandwijk, J. H. Beijnen, and J. H. M. Schellens Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2237 - 2244. [Abstract] [Full Text] [PDF]

				M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, M. Germani, I. Poggesi, and M. Rocchetti Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents Cancer Res., February 1, 2004; 64(3): 1094 - 1101. [Abstract] [Full Text] [PDF]

				J. M. Gallo, S. Li, P. Guo, K. Reed, and J. Ma The Effect of P-glycoprotein on Paclitaxel Brain and Brain Tumor Distribution in Mice Cancer Res., August 15, 2003; 63(16): 5114 - 5117. [Abstract] [Full Text] [PDF]

				A. Sparreboom, A. C. Wolff, J. Verweij, Y. Zabelina, D. M. van Zomeren, G. L. McIntire, C. S. Swindell, R. C. Donehower, and S. D. Baker Disposition of Docosahexaenoic Acid-Paclitaxel, a Novel Taxane, in Blood: In Vitro and Clinical Pharmacokinetic Studies Clin. Cancer Res., January 1, 2003; 9(1): 151 - 159. [Abstract] [Full Text] [PDF]

				W. L. Chiou, T. C. Wu, C. Ma, H. Y. Jeong, M.M. Malingre, J.H. Beijnen, and J.H.M. Schellens Enhanced Oral Bioavailability of Docetaxel by Coadministration of Cyclosporine: Quantitation and Role of P-Glycoprotein J. Clin. Oncol., April 1, 2002; 20(7): 1951 - 1952. [Full Text] [PDF]

				D. S. Schrump, S. Zhai, D. M. Nguyen, T. S. Weiser, B. A. Fisher, R. E. Terrill, B. M. Flynn, P. H. Duray, and W. D. Figg Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 686 - 694. [Abstract] [Full Text] [PDF]

				H. Gelderblom, J. Verweij, D. M. van Zomeren, D. Buijs, L. Ouwens, K. Nooter, G. Stoter, and A. Sparreboom Influence of Cremophor EL on the Bioavailability of Intraperitoneal Paclitaxel Clin. Cancer Res., April 1, 2002; 8(4): 1237 - 1241. [Abstract] [Full Text] [PDF]

				E. Auzenne, N. J. Donato, C. Li, E. Leroux, R. E. Price, D. Farquhar, and J. Klostergaard Superior Therapeutic Profile of Poly-L-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma Clin. Cancer Res., February 1, 2002; 8(2): 573 - 581. [Abstract] [Full Text] [PDF]

				H. Gelderblom, K. Mross, A. J. ten Tije, D. Behringer, S. Mielke, D. M. van Zomeren, J. Verweij, and A. Sparreboom Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions J. Clin. Oncol., January 15, 2002; 20(2): 574 - 581. [Abstract] [Full Text] [PDF]

				A. Henningsson, M. O. Karlsson, L. Vigano, L. Gianni, J. Verweij, and A. Sparreboom Mechanism-Based Pharmacokinetic Model for Paclitaxel J. Clin. Oncol., October 15, 2001; 19(20): 4065 - 4073. [Abstract] [Full Text] [PDF]

				P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, A. H. Calvert, D. R. Newell, and N. J. Curtin In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity Clin. Cancer Res., July 1, 2001; 7(7): 2105 - 2113. [Abstract] [Full Text] [PDF]

				M. Hidalgo, C. Aylesworth, L. A. Hammond, C. D. Britten, G. Weiss, J. Stephenson Jr, G. Schwartz, A. Patnaik, L. Smith, K. Molpus, et al. Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel J. Clin. Oncol., May 1, 2001; 19(9): 2493 - 2503. [Abstract] [Full Text] [PDF]

				G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231. [Abstract] [Full Text] [PDF]

				H. A. Bardelmeijer, J. H. Beijnen, K. R. Brouwer, H. Rosing, W. J. Nooijen, J. H. M. Schellens, and O. van Tellingen Increased Oral Bioavailability of Paclitaxel by GF120918 in Mice through Selective Modulation of P-glycoprotein Clin. Cancer Res., November 1, 2000; 6(11): 4416 - 4421. [Abstract] [Full Text] [PDF]

				C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468. [Abstract] [Full Text]

				M. M. Malingre, J. M. M. Terwogt, J. H. Beijnen, H. Rosing, F. J. Koopman, O. van Tellingen, K. Duchin, W. W. T. B. Huinink, M. Swart, J. Lieverst, et al. Phase I and Pharmacokinetic Study of Oral Paclitaxel J. Clin. Oncol., June 12, 2000; 18(12): 2468 - 2475. [Abstract] [Full Text] [PDF]

				H. Gelderblom, J. Verweij, E. Brouwer, M. Pillay, P. de Bruijn, K. Nooter, G. Stoter, and A. Sparreboom Disposition of [G-3H]paclitaxel and Cremophor EL in a Patient with Severely Impaired Renal Function Drug Metab. Dispos., November 1, 1999; 27(11): 1300 - 1305. [Abstract] [Full Text]

				J. M. Meerum Terwogt, M. M. Malingre, J. H. Beijnen, W. W. ten Bokkel Huinink, H. Rosing, F. J. Koopman, O. van Tellingen, M. Swart, and J. H. M. Schellens Coadministration of Oral Cyclosporin A Enables Oral Therapy with Paclitaxel Clin. Cancer Res., November 1, 1999; 5(11): 3379 - 3384. [Abstract] [Full Text] [PDF]

				O. v. Tellingen, J. H. Beijnen, J. Verweij, E. J. Scherrenburg, W. J. Nooijen, and A. Sparreboom Rapid Esterase-sensitive Breakdown of Polysorbate 80 and Its Impact on the Plasma Pharmacokinetics of Docetaxel and Metabolites in Mice Clin. Cancer Res., October 1, 1999; 5(10): 2918 - 2924. [Abstract] [Full Text] [PDF]

				V. R N. Panday, M. T Huizing, O. van Tellingen, R. A Hakvoort, P. H B Willemse, A. De Graeff, J. B Vermorken, and J. H Beijnen Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel Journal of Oncology Pharmacy Practice, June 1, 1999; 5(2): 83 - 86. [Abstract] [PDF]

				L. R. Duska, R. Penson, J. G. Supko, D. M. Finkelstein, T. Makastorsis, J. Gallagher, K. Borden, A. Goodman, A. F. Fuller, N. Nikrui, et al. A Phase I Study of Continuous Infusion Doxorubicin and Paclitaxel Chemotherapy with Granulocyte Colony-Stimulating Factor for Relapsed Epithelial Ovarian Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1299 - 1305. [Abstract] [Full Text] [PDF]

				M. Esposito, M. Venturini, M.O. Vannozzi, G. Tolino, G. Lunardi, O. Garrone, C. Angiolini, M. Viale, M. Bergaglio, L. Del Mastro, et al. Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients J. Clin. Oncol., April 1, 1999; 17(4): 1132 - 1132. [Abstract] [Full Text] [PDF]

				A. Sparreboom, L. van Zuylen, E. Brouwer, W. J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications Cancer Res., April 1, 1999; 59(7): 1454 - 1457. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]

				R. Kawai, D. Mathew, C. Tanaka, and M. Rowland Physiologically Based Pharmacokinetics of Cyclosporine A: Extension to Tissue Distribution Kinetics in Rats and Scale-up to Human J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 457 - 468. [Abstract] [Full Text]

				B. Monsarrat, E. Chatelut, I. Royer, P. Alvinerie, J. Dubois, A. Dezeuse, H. Roché, S. Cros, M. Wright, and P. Canal Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4 Drug Metab. Dispos., March 1, 1998; 26(3): 229 - 233. [Abstract] [Full Text]

				L. K Webster, D. M Woodcock, D. Rischin, and M. J Millward Review : Cremophor: Pharmacological activity of an "inert" solubiliser Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 186 - 192. [Abstract] [PDF]

				Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]

				A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. A. M. Mol, L. van Deemter, J. J. M. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins PNAS, April 15, 1997; 94(8): 4028 - 4033. [Abstract] [Full Text] [PDF]

				A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine PNAS, March 4, 1997; 94(5): 2031 - 2035. [Abstract] [Full Text] [PDF]